Skip to main content

Celyad S.A. (CYAD)

NASDAQ: CYAD · Delayed Price · USD
4.33 0.06 (1.41%)
Sep 22, 2021 4:00 PM EDT - Market closed
Market Cap66.58M
Revenue (ttm)n/a
Net Income (ttm)-18.41M
Shares Out15.49M
EPS (ttm)-1.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,842
Open4.28
Previous Close4.27
Day's Range4.28 - 4.34
52-Week Range3.76 - 10.31
Beta1.31
AnalystsStrong Buy
Price Target19.00 (+338.8%)
Est. Earnings Daten/a

About CYAD

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T thera...

IndustryBiotechnology
Founded2004
CEOFilippo Petti
Employees87
Stock ExchangeNASDAQ
Ticker SymbolCYAD
Full Company Profile

Financial Performance

In 2020, Celyad's revenue was 5,000, a decrease of -16.67% compared to the previous year's 6,000. Losses were -17.20 million, -39.91% less than in 2019.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for Celyad stock is "Strong Buy." The 12-month stock price forecast is 19.00, which is an increase of 338.80% from the latest price.

Price Target
$19.00
(338.80% upside)
Analyst Consensus: Strong Buy

News

Celyad Oncology Announces September 2021 Conferences Schedule

MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ...

3 weeks ago - GlobeNewsWire

Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developme...

1 month ago - GlobeNewsWire

Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium, July 29, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

1 month ago - GlobeNewsWire

Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Rese...

MONT-SAINT-GUIBERT, Belgium, July 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Celyad Oncology or the Company), a clinical-stage biotechnology company focused on the discov...

2 months ago - GlobeNewsWire

Celyad Oncology to Host Virtual Research & Development Webinar on July 20th

MONT-SAINT-GUIBERT, Belgium, July 13, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

2 months ago - GlobeNewsWire

Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021

MONT-SAINT-GUIBERT, Belgium, July 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

2 months ago - GlobeNewsWire

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYA...

MONT-SAINT-GUIBERT, Belgium, June 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

3 months ago - GlobeNewsWire

Celyad Oncology Announces June 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric an...

3 months ago - GlobeNewsWire

Transparency notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, May 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric an...

4 months ago - GlobeNewsWire

Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy

Celyad Oncology SA (NASDAQ: CYAD) has announced initial clinical data from the Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in patients with relapsed or refractory multiple myeloma. The data will be pre...

4 months ago - Benzinga

Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 ...

MONT-SAINT-GUIBERT, Belgium, May 12, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric an...

4 months ago - GlobeNewsWire

Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, May 06, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developmen...

4 months ago - GlobeNewsWire

Transparency Notification Received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, May 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric an...

4 months ago - GlobeNewsWire

Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer

MONT-SAINT-GUIBERT, Belgium, April 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ...

5 months ago - GlobeNewsWire

Celyad Oncology Announces April 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, April 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ...

5 months ago - GlobeNewsWire

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, March 31, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ...

5 months ago - GlobeNewsWire

Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, March 24, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ...

5 months ago - GlobeNewsWire

Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

6 months ago - Business Wire

Celyad Oncology Announces March 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, March 01, 2021 (GLOBE NEWSWIRE) -- Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discover...

6 months ago - GlobeNewsWire

Celyad Oncology Announces March 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

6 months ago - Business Wire

Celyad Oncology Announces February 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

7 months ago - Business Wire

Celyad Oncology Announces February 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

7 months ago - GlobeNewsWire

Information on the Total Number of Voting Rights and Shares (Articles 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

8 months ago - GlobeNewsWire

Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...

Other symbols:ACRSGRTSMRUSNERVTENX
8 months ago - Benzinga

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

MONT-SAINT-GUIBERT, Belgium, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

8 months ago - GlobeNewsWire